Jiangsu Recbio Expects REC603 HPV Vaccine Launch in 2029-2030 as Clinical Data Collection Takes Longer

PUBT · 11/09 08:50
Jiangsu Recbio Expects REC603 HPV Vaccine Launch in 2029-2030 as Clinical Data Collection Takes Longer
  • Jiangsu Recbio missed its planned marketing application timetable for REC603, its nine-valent HPV vaccine candidate, because clinical endpoint collection is taking longer.
  • Lower HPV infection rates and expanded cervical screening slowed endpoint accrual, requiring longer Phase III follow-up in China.
  • Commercial launch is expected between 2029 and 2030, subject to successful development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Recbio Technology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261109-12405394), on November 09, 2026, and is solely responsible for the information contained therein.